Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;7(5):349-54.
doi: 10.1038/cmi.2010.33. Epub 2010 Jul 26.

Identification of two aberrant transcripts derived from a hybridoma with amplification of functional immunoglobulin variable genes

Affiliations

Identification of two aberrant transcripts derived from a hybridoma with amplification of functional immunoglobulin variable genes

Guipeng Ding et al. Cell Mol Immunol. 2010 Sep.

Abstract

Murine monoclonal antibodies (mAbs) are widely used but have limitations if administered in humans. The use of chimeric or humanized mAbs can reduce immunogenicity. The first step in producing such mAbs is to clone murine variable genes from a hybridoma, but it is possible to amplify both functional and aberrant variable genes, as they coexist in the hybridoma. During the development of a murine-human chimeric antibody, we have cloned from a hybridoma the functional heavy chain variable region (V(H)) and light chain variable region (V(L)) genes of a mAb that blocks the binding of anthrax lethal factor to protective antigen. In this study, we report the detection of two aberrant transcripts from a hybridoma produced using myeloma cell line OUR-1, the development of a method to distinguish between the functional and abundant aberrant V(L) transcripts, and the origins of these aberrant genes. The aberrant V(L) gene is derived from OUR-1 cells, while the aberrant V(H) gene might derive from antibody repertoires in B cells or from gene rearrangement in the hybridoma cells. The aberrant V(H) and V(L) genes in this study may facilitate discrimination between the functional and aberrant variable genes from hybridoma cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Agarose gel electrophoresis of PCR products of variable genes. Murine VH and VL genes were amplified from FR1 to FR4 by reverse transcription PCR from hybridoma cells. GAPDH was an internal control. Lane M: DNA marker; lane 1: GAPDH; lane 2: VH; lane 3: VL. FR, framework region; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Figure 2
Figure 2
Agarose gel electrophoresis of the VL PCR product before and after BciVI digestion. Purified PCR product of the VL gene was digested by BciVI to isolate the functional VL gene. After incubation overnight at 37 °C, most of the product was cut to form two bands of approximately 180 and 190 bp. Non-cut products were rare.
Figure 3
Figure 3
Agarose gel electrophoresis of eight TA plasmids containing VL digested again by BciVI. Eight TA plasmids containing VL were digested by BciVI. Three (nos. 2, 5 and 7) were cut into two fragments, indicating no cut in VL (functional VL gene). Five plasmids (nos. 1, 3, 4, 6 and 8) cut into three fragments carried the same aberrant gene.
Figure 4
Figure 4
Agarose gel electrophoresis of PCR products of VH genes using different sense primers. Murine VH genes were amplified from signal sequence to FR4 by reverse transcription PCR using different sense primers and the same antisense primer. Lane M: DNA marker; lane 1: mixture of three MHALT primers; lane 2: MHALT1; lane 3: MHALT2; lane 4: MHALT3. FR, framework region.
Figure 5
Figure 5
Agarose gel electrophoresis of PCR products of VL genes using different sense primers. Murine VL genes were amplified from signal sequence to FR4 by reverse transcript PCR using different sense primers and the same antisense primer. Lane M: DNA marker; lane 1: mixture of five MLALT primers; lane 2: MLALT1; lane 3: MLALT2; lane 4: MLALT3; lane 5: MLALT4; lane 6: MLALT5. FR, framework region.
Figure 6
Figure 6
Alignment of the DNA sequences of abVH-LF8 (HM046413) with other VH genes. The DNA sequence of aberrant abVH-LF8 was aligned with an aberrant VH gene (EU121635) and two functional VH genes (U60820 and AY646832). Signal sequences are underlined and complementarity-determining regions of functional genes are shadowed. Gaps are represented by dashes, identical bases by *.
Figure 7
Figure 7
Agarose gel electrophoresis of functional and aberrant VH and VL genes using different sense primers and corresponding antisense primer. Lane M: DNA marker; lane F: functional variable genes (sense primer MHALT1 for VH and sense primer MLALT2 for VL); lane A: aberrant variable genes (sense primer MHALT3 for VH and sense primer MLALT1 for VL).

Similar articles

Cited by

References

    1. Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, et al. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res. 2010;16:1915–1923. - PubMed
    1. Azinovic I, DeNardo GL, Lamborn KR, Mirick G, Goldstein D, Bradt BM, et al. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother. 2006;55:1451–1458. - PMC - PubMed
    1. Chen Z, Moayeri M, Crown D, Emerson S, Gorshkova I, Schuck P, et al. Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun. 2009;77:3902–3908. - PMC - PubMed
    1. Riley CJ, Engelhardt KP, Saldanha JW, Qi W, Cooke LS, Zhu Y, et al. Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res. 2009;69:1933–1940. - PMC - PubMed
    1. Huang YJ, Chen IC, Yu CM, Lee YC, Hsu HJ, Ching AT, et al. Engineering anti-vascular endothelial growth factor single chain disulfide-stabilized antibody variable fragments (sc-dsFv) with phage-displayed sc-dsFv libraries. J Biol Chem. 2010;285:7880–7891. - PMC - PubMed

Substances